Table of Contents
1. Introduction2. Diagnosis of AIHAs and differential diagnosis of hemolysis
3. Classification of AIHAs
4. Clinical presentation of AIHAs
5. Standard treatment of AIHAs
6. Novel treatment strategies of AIHAs
7. Complications of AIHAs
9. Management of special situations
10. Conclusion
Authors
Wilma Barcellini IRCCS Ospedale Maggiore Policlinico Foundation, Italy.Wilma Barcellini, an Associate Professor specializing in Blood Diseases, Oncology, and Rheumatology, serves as Director of the Pathophysiology of Anemia Unit at IRCCS Ospedale Maggiore Policlinico Foundation. She specializes in diagnosing and treating immuno-mediated cytopenias and rare anemias. Barcellini leads Research Projects funded by renowned institutions like IRCCS Ospedale Maggiore Policlinico Foundation, Istituto Superiore di Sanit�, and the Ministry of Health. She's a distinguished member of the European Network for Rare and Congenital Anemias. In the 1980s and 1990s, she gained experience as a Visiting Scientist at the Laboratories of Immunology under Professors RH Zubler at the University Hospital Geneva, Switzerland, and A Dalgleish at St George's Hospital, University of London, UK.
Bruno Fattizzo IRCCS Ospedale Maggiore Policlinico Foundation and University of Milano, Italy.Bruno Fattizzo, a dedicated Hematologist and Assistant Professor at Policlinico Hospital and the University of Milan, Italy, centers his clinical and research endeavors on autoimmune cytopenias, notably autoimmune hemolytic anemia (AIHA), immune thrombocytopenia, autoimmune neutropenia, and Evans syndrome. His focus extends to bone marrow failure syndromes like paroxysmal nocturnal hemoglobinuria (PNH), aplastic anemia, and myelodysplastic syndromes (MDS). During a research stint at King's College Hospital in London, Fattizzo delved into bone marrow failure syndromes, specifically exploring the clinical and prognostic implications of small PNH clones. He boasts an authorship of over 135 publications in indexed journals. Fattizzo also spearheads clinical trials involving innovative drugs tailored for AIHA, PNH, and MDS, showcasing his commitment to advancing treatment modalities in these conditions.